 control trial vidarabin acyclovir neonat herp simplex viru infect infecti diseas collabor antivir studi group background use vidarabin simplex viru hsv infect neonat diseas high morbid mortal control trial vidarabin acyclovir treatment neonat hsv infect method babi month age hsv infect intraven vidarabin mg kilogram bodi weight day acyclovir mg day day actuari rate mortal morbid survivor year overal extent diseas entri studi infect skin eye mouth diseas result adjust differ group extent diseas differ vidarabin acyclovir morbid mortal none babi diseas skin eye die babi group vidarabin year percent year percent acyclovir percent confid interv differ babi enceph mortal percent vidarabin acyclovir survivor percent percent year percent confid interv differ babi dissemin diseas mortal percent vidarabin percent acyclovir percent confid interv differ survivor percent percent year percent confid interv differ medic seriou toxic effect conclus multicent studi differ outcom vidarabin acyclovir treatment neonat hsv infect studi statist power sizabl differ subgroup local hsv enceph dissemin diseas